These results suggest that, in prostate cancer, the increase in the fumarate level might trigger carcinogenesis, partly via the HIF1α and NFκB pathways, which have crucial clinical relevance in patients with prostate cancer. This evidence concerns the gene HIF1A and prostate cancer.